1Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group [J]. J Clin Oncol, 2009,27( 1 ) :61-69.
2Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial [J]. Blood, 2007,109 (12) : 5129-5135.
3Faderl S, Ravandi F, Huang X, et al. A randomized study of Clofarabine versus Clofarabine plus low-dose Cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome [J]. Blood, 2008,112(5) : 1638-1645.
4Baer MR, George SL, Caligiuri MA, et al. Low-dose Interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720 [J]. J Clin Oncol, 2008,26(30):4934-4939.
5Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2 169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 [J]. Blood, 2008,111 (9):4477-4489.
6Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph +ALL) [J]. Cancer, 2007,109 (10) : 2068-2076.
7Pulsoni A, Iacobelli S, Bernardi M, et al. M4 acute myeloid leukemia: The role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience [J]. Haematologica, 2008,93(7) : 1025-1032.
